Over 130 million doses have already been administered worldwide. It’s early days, but the signs are promising in places like Israel and the UK.
L’expertise universitaire, l’exigence journalistique
Articles sur COVID-19 vaccines
Affichage de 421 à 440 de 576 articles
The arrival of COVID-19 vaccines has raised hope for an end to the pandemic. Hopefully that’s true, but there are variables. Here are some factors that could affect the success of the vaccine rollout.
Advocates for medicines that are unregistered in South Africa have accused the regulatory authority of not being proactive in bringing such products to market and approving their use.
These variants are definitely cause for concern. But there’s every indication we can adapt our vaccine strategy to combat these and other variants going forward.
Behind Canada’s current COVID-19 vaccine shortage is a decades-long tale of unheeded warnings, missed opportunities and dismantled resources that was never going to end well.
Early numbers show that people from racial and ethnic minorities have lower vaccination rates. Lack of internet access could be a reason.
Americans with excess weight and obesity have been hit hard by COVID-19. Now there is reason to believe they may not get the same protection from the vaccines.
Women, particularly those of childbearing age, were more likely to be unsure about getting vaccinated.
Vaccine selfies are just the tip of the iceberg of doctor frustration over Canada’s fragmented vaccine rollout.
Giving money to support local production of COVID-19 vaccines is a step in the right direction if it will help in resuscitating Nigeria’s vaccine production laboratory.
A new study argues for selective border relaxations. But with COVID-19 more prevalent now than at almost any point in the past, the risk would be substantial.
Researchers are already working to improve the current crop of mRNA vaccines. Hopefully this will help them become more practical and affordable for the entire world, not just first-world countries.
Vaccines should be seen as a kind of foreign aid.
After a dispute with AstraZeneca, the European Commission is restricting access to vaccines made within its borders.
It’s going to be a huge logistical challenge.
The approval of the first of four COVID-19 vaccines marks the first step in New Zealand’s plans for a Pacific-wide immunisation rollout.
By prioritising vaccination for the elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amid a limited vaccine supply during the first vaccination phase.
The results indicate that the vaccine efficacy in the UK was 89% for individuals who received at least two doses of vaccine. In South Africa, the vaccine efficacy was 60% in people without HIV.
A recommendation from a German vaccine advisory body not to give the AstraZeneca vaccine to people aged over 65 has caused concern. But we should interpret this advice with caution.
The conflict shows just how high the political stakes are on all sides.
Les contributeurs les plus fréquents
-
Associate professor, UNSW Sydney
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Joel Lexchin est un·e ami·e de La Conversation
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor, Epidemiology, Deakin University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Assistant Professor of Political Science, Oklahoma State University
-
Instructor of Human Immunology, Emory University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Chair in Epidemiology, Deakin University
